NASDAQ · Biotechnology · USD

Moolec Science SA (MLEC) Stock Analysis

Moolec Science SA (MLEC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MLEC

$1.67

+$0.07 (+4.37%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MLEC with… →

MLEC Key Statistics

As of Oct 21, 2026

Trading

Open: $1.66
Previous Close: $1.60
Day's Range: 1.63–1.71
52-Week Range: 1.48–23.22
Volume: 7.81K

Valuation

Market Cap: $1.21M
P/E Ratio: unprofitable
EPS (ttm): −199.02

Financials (FY)

Revenue (FY): $333.61M−28.47%
Net Income (FY): −$111.46M
Shares Outstanding: 726.12K
1-Year Return: −82.63%

Dividend and dates

Avg Volume: 36.46K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MLEC closed at $1.67, −82.63% over 1 year.

Moolec Science SA (MLEC) has a market capitalization of $1.21M.

In fiscal 2025, MLEC reported revenue of $333.61M.

MLEC Stock Return by Calendar Year

Moolec Science SA (MLEC) return since Mar 2021: what $10,000 became

1 year: $10,000 $1,737; −82.63%
5 years: $10,000 $11; −99.89%
Since Mar 2021: $10,000 $11; −99.89%

If you had invested $10,000 in Moolec Science SA (MLEC) at the close on March 2, 2021, the earliest close on record here, it would have been worth $11 at the close on October 21, 2026: −99.89% in total, −69.97% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+0.51%+22.72%−79.67%−67.48%−96.81%−56.34%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−56.34%
2025	−96.81%
2024	−67.48%
2023	−79.67%
2022	+22.72%
2021 (partial year)	+0.51%

As of October 21, 2026.

MLEC Revenue and Earnings by Fiscal Year

FY ends June

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$333.61M	−$111.46M	−33.4%
2024	$466.38M	−$32.69M	−7.0%
2023	$420.87M	$40.44M	9.6%
2022	$0.00	−$4.53M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$333.61M	$125.74M	−$3.51M	−$111.46M	−33.4%
2024	$466.38M	$179.31M	$41.76M	−$32.69M	−7.0%
2023	$420.87M	$179.22M	$50.61M	$40.44M	9.6%
2022	$0.00	$0.00	−$3.65M	−$4.53M	—

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

Analysis

Data-derived

Company Overview

The market values Moolec Science SA (MLEC) at $1.21M. The company sits in the Healthcare sector, in the Biotechnology industry.

MLEC last closed at $1.67 on October 21, 2026. That is +$0.07 (+4.37%) against the previous close. Over the past 52 weeks the price has ranged from $1.48 to $23.22. The latest close sits 12.76% above that 52-week low.

Financial Health

In fiscal 2025, Moolec Science SA reported revenue of $333.61M. Against the prior fiscal year total of $466.38M, that is a change of −28.47%. The same year closed with a net loss of $111.46M. Earnings per share on a trailing basis come to −199.02.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $333.61M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Annualized volatility over the trailing 5 years is 174.6%. Over the trailing twelve months the total return is −82.63%. Across 5 years the annualized return works out at −74.25%.

Growth & Income

No dividend is on file for MLEC.

So far in 2026 the total return is −56.34%. The strongest complete calendar year on file is 2022 at +22.72%; the weakest is 2025 at −96.81%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Moolec Science SA (MLEC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Moolec Science SA	MLEC	$1.21M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Moolec Science SA has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Moolec Science SA

Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas. The company is based in Grand Cayman, Cayman Islands.

Visit website →